每经记者｜赵李南 每经编辑｜文多 4月6日，钟南山在厦门大学100周年校庆活动上作了主题为《新冠防控策略与疫苗研发》的讲座。他呼吁，应当坚决接种疫苗。 钟南山表示，目前我国新冠疫苗接种比例只有百分之九点几。他认为，接种疫苗是应对接下来的经济开放的必然要求。 此外，钟南山认为，病毒的变异也给接下来的防疫工作带来了挑战，一方面毒株的变异会导致疫苗失效，另外一方面，病毒变异也影响抗体治疗的效果。 呼吁坚决接种疫苗 "中国是多少呢？只有百分之九点多（接种疫苗比例）。太低了，为什么这么低呢？两个原因，一是很多中国人觉得有什么必要接种疫苗？觉得很安全，根 本没有必要；另外一个担心有副作用。但实际上，假如大家想象一下，所有国家都接种了疫苗，你将来再开放的话，中国绝大部分人是无免疫状态，那这时 候很容易传进来，中国（将）会又暴发，那不得了。所以我们在接种疫苗这方面应该非常坚决。"钟南山表示。 病毒的变异带来挑战 "到现在为止，没有人知道这几个疫苗能够持续有效多长时间，都是未知数。"钟南山说道，给疫苗有效时间带来不确定的最大因素，就是病毒正在发生变 异。 钟南山讲座PPT（1） 图片来源：每经记者 赵李南 摄 钟南山讲座PPT ...

21世纪经济报道记者张欣 与顶尖经济学家相遇是何种体验？北京初冬的午后，中央财经大学讲堂内座无虚席，就连过道和走廊也 挤满了人。大家静候的，正是2025年诺贝尔经济学奖获得者菲利普·阿吉翁（Philippe Aghion）。这位 用"创造性破坏"重构增长理论的经济学家，即将带来一场融合学术深度与人格温度的思想盛宴。 菲利普·阿吉翁（以下简称"阿吉翁"）的名字，早已与现代增长理论紧密相连。这位1956年出生的法国 经济学家，拥有巴黎高等师范学院数学经济学博士学位、美国哈佛大学博士学位，曾先后在麻省理工学 院、哈佛大学等世界顶尖高校任教，现任欧洲工商管理学院，法兰西学院和伦敦经济学院教授。 学术生涯中，他最核心的贡献便是与彼得·豪伊特等人共创"创新驱动增长理论"，将熊彼特"创造性破 坏"概念模型化、体系化，打破了索洛模型长期垄断增长理论领域的局面，这一突破也让他斩获2025年 诺贝尔经济学奖。 出身于法国时尚品牌Chloe创始人家庭的阿吉翁，自幼便在"颠覆传统"的创新氛围中成长，母亲以简约 设计打破时尚界陈规的经历，更潜移默化地塑造了他批判性审视主流理论的学术品格。从学术殿堂的理 论构建者，到全球经济发展的建言人 ...

Core Viewpoint - The article discusses the rise of Chinese pharmaceutical companies in innovation and the challenges they face in collaborating with research institutions, highlighting a trust crisis in early-stage academic innovations [4][5][6]. Group 1: Innovation in Chinese Pharmaceutical Industry - In 2023, the total amount of new drug licensing transactions from Chinese pharmaceutical companies has exceeded $100 billion, indicating a significant rise in innovation capabilities [4]. - The market's increasing demand for innovation is leading to a more competitive international landscape for Chinese pharmaceutical companies [4]. Group 2: Challenges in Collaboration - Domestic research universities and institutions often face difficulties in industrial collaboration, with most partnerships occurring only after projects have reached advanced stages [5][6]. - There is a notable contrast with the U.S., where academic innovations are more readily supported by venture capital, reflecting a conservative approach in China towards early-stage academic innovations [5][6]. Group 3: Trust Issues and Funding - Trust issues arise when early-stage academic research fails to meet expectations, leading to terminated collaborations and a lack of investment in promising projects [7][12]. - The funding required for preclinical research ranges from 30 million to 50 million yuan, which poses a significant barrier for many projects [12]. Group 4: Need for Differentiated Investment - It is suggested that venture capital and large pharmaceutical companies allocate 5% to 10% of their R&D budgets to support early-stage, differentiated innovations, which could lead to breakthrough results [13]. - The article emphasizes the importance of nurturing both immediate and long-term innovations in the pharmaceutical industry, akin to planting seeds for future growth [13].

在笔者此前写的" 从哈雷到AI "一文中，我提到过一个颇具戏剧性的细节。英国的天文学家哈雷在机缘巧合之下，收到了一份来自德国的死亡登记表，上面 记录了一个小城 布雷斯 劳城 20 多年来的出生与死亡纪录。它看上去毫不起眼，却成为精算统计的起点。数学第一次能够量化生命的长短，甚至可以预测 人口的变化。 如果说这段历史让人感慨万千，那么接下来发生的事更加有趣。在 17 世纪末，我们人类掌握的数学知识，已经可以让我们完全有能力去定价寿险。然后寿 险真正被商业世界接受，却还要再等上 50 年，直到18世纪中叶。 50 年是很长的时间，足够让一个国家经历两次战争，也足够让一门科学从新奇变成必需。科学比市场早到了半个世纪，这种延迟并非技术原因，而是人性 的节奏。保险业的故事告诉我们， 世界并不总按照科学的速度前进，而是常常按照公众的心理速度前进 。 要理解这一段延迟，我们必须回到寿命表本身。哈雷在 1693 年整理并发表了《人类死亡概率估算》，首次利用大量死亡数据计算不同年龄段的死亡概率 【1】。一个 30 岁男性一年内死亡的概率是多少。5 岁儿童的生存率是多少。80 岁老人再活 10 年的机会有多大。数学首次揭示，死亡 ...

Core Viewpoint - The company has no plans for acquisition and is focused on its long-term development while enhancing its core competitiveness in the vaccine sector [2] Group 1: Company Strategy - The company emphasizes high-quality development and is actively advancing its research, production, and sales efforts [2] - The company is committed to improving its product pipeline, particularly in adult vaccines, multi-valent vaccines, and mRNA vaccines [2] Group 2: Market Environment - The company acknowledges the opportunities and challenges presented by an aging population and the emergence of new technologies and products [2] - The company aims to enhance its investment value and shareholder return capabilities based on quality improvement [2]

Group 1 - The company is progressing as planned with the development of mRNA vaccines for treating glioblastoma and rhabdomyosarcoma, with the current progress meeting expectations [1] - Investors are inquiring about the status of the tumor vaccine, indicating interest and anticipation regarding the company's developments [1]

Core Viewpoint - Agna Biopharmaceuticals, a Chinese biotech company, is preparing for an IPO in Hong Kong, aiming to raise several hundred million dollars [1] Company Overview - Agna Biopharmaceuticals was established in 2021 and is headquartered in Guangzhou, Guangdong Province [1] - The company focuses on RNAi drugs and mRNA vaccines, leveraging the potential of RNA technology [1] - Agna has developed a diverse range of RNA combinations and efficient drug delivery systems targeting infectious diseases, metabolic diseases, cardiovascular diseases, malignant tumors, and rare diseases [1] Production Capacity - With support from local government, Agna Biopharmaceuticals has built an advanced production line capable of producing over 500 million doses of mRNA vaccines annually [1] IPO Details - The company is collaborating with several investment banks, including Bank of America, CICC, Jefferies, and JPMorgan, for its IPO [1] - Agna has submitted a confidential IPO application, with specific details regarding the scale and timing still under discussion [1]

Core Viewpoint - Agna Biopharmaceuticals, a Chinese biotech company, is planning an IPO in Hong Kong with potential fundraising of several hundred million dollars [1] Company Overview - Agna Biopharmaceuticals was established in 2021 and is headquartered in Guangzhou, Guangdong Province [1] - The company focuses on RNAi drugs and mRNA vaccines, leveraging the potential of RNA and its diverse RNA combinations along with efficient drug delivery systems [1] - Agna is developing RNA drugs and vaccines for infectious diseases, metabolic diseases, cardiovascular diseases, malignant tumors, and rare diseases [1] Production Capacity - With support from the local government, Agna has built an advanced production line capable of producing over 500 million doses of mRNA vaccines annually [1] IPO Details - The company is collaborating with major investment banks including Bank of America, CICC, Jefferies, and JPMorgan for its IPO [1] - Agna has submitted a confidential IPO application, with specific details regarding scale and timing still under discussion [1]

Market Performance Summary - Sinopec Oilfield Service (01033) rose over 12% as the company continues to advance its overseas strategy, with new contract signings increasing by over 70% in the first half of the year [1] - China Hongqiao Group (00931) fell over 13% after a significant 55% surge the previous day, with ongoing discussions regarding potential investments [1] - BYD Electronic (00285) increased over 4% as the company is set to supply power components for NVIDIA's new 800VDC AI server architecture [1] - Horizon Robotics-W (09660) rose over 6% as its HSD technology was first adopted by the ET5 model, with multiple automakers already confirming orders [1] - Bilibili-W (09626) increased over 10% due to strong performance of new games, indicating a gradual release of its commercial value [1] - CRRC Corporation (01766) rose nearly 4% ahead of its third-quarter earnings report, with expectations for continued growth in new train procurement and maintenance [1] - Genscript Biotech (01952) rose over 5% as its EVM14 treatment for squamous cell carcinoma addresses critical clinical needs, leading in clinical development progress [1] - Bosideng (03998) increased nearly 6% following the appointment of renowned British designer Kim Jones as the creative director for its new AREAL high-end urban line [1] - Derin Holdings (01709) fell over 11% after announcing a discounted placement of shares to raise funds for expanding Bitcoin mining operations [1] US Market Highlights - TSMC (TSM.US) rose 0.89% as the first NVIDIA Blackwell wafers were recently produced in the US [3] - Pony.ai (PONY.US) increased 1.76% after partnering with Stellantis for autonomous vehicle solutions [3] - WeRide (WRD.US) rose 2.67% after successfully passing the Hong Kong Stock Exchange hearing, positioning itself to become the first "Robotaxi" stock in Hong Kong [3] - Zeekr (ZK.US) increased 4.48% as pre-sales for the refreshed Zeekr 7X officially began, offering significant pre-sale benefits [3] - iQIYI (IQ.US) rose 8.37% as Morgan Stanley upgraded its target price, citing the long-term growth potential of the domestic IP merchandise market [3] - Taoping (TAOP.US) increased 4.27% after announcing a non-binding letter of intent to acquire 100% of Alphalion Holding Limited [3] - Micron Technology (MU.US) rose 2.17% as several major firms raised their target prices for the company [4] - U.S. Antimony Corporation (UAMY.US) surged 20.02% following its proposal to acquire Larvotto Resources to enhance its critical mineral asset portfolio [4] - Apple (AAPL.US) rose 3.94% as a report indicated strong early sales of the iPhone 17 series in China and the U.S. [4] - Moderna (MRNA.US) increased 4.73% after presenting positive data on its mRNA vaccine pipeline at the IDWeek 2025 conference [4]

Core Viewpoint - China Pharmaceutical University is implementing the "101 Plan" to establish a comprehensive talent training system in pharmacy that integrates life and disease cognition, basic research, industrial transformation, and clinical application [2][9]. Organized Research and Innovation - The university is transitioning from a free exploration model to an organized research approach to enhance drug development efficiency, addressing the complexities of new drug research [3][4]. - An action plan for organized research has been launched, integrating innovation elements and focusing on key technology challenges [4]. - Eight technology innovation centers and sixteen research tracks have been established to facilitate collaboration from basic research to clinical application [4]. Talent Development - The university is innovating its talent training by implementing a project-based mentorship system, encouraging collaborative research among students [5][9]. - The "101 Plan" aims to produce versatile talents who are well-versed in both theory and practice, addressing the needs of the pharmaceutical industry [9][10]. Technology Transfer and Industry Collaboration - The university has initiated the "Pharmaceutical Concept Validation Plan" to provide comprehensive validation services for innovative drug projects, successfully converting over 30 projects [6][7]. - The establishment of the Nanjing Jiangbei Innovation Center aims to enhance the industrial application of life sciences, attracting enterprises to develop research and production centers [6][7]. Original Drug Development - The university focuses on developing original drugs tailored to the genetic and health characteristics of the Chinese population, addressing unmet clinical needs [13][14]. - Innovative drugs such as VikaGrel and AAPB are being developed to improve treatment efficacy and patient outcomes [14][15]. Traditional Chinese Medicine Innovation - The university is advancing the modernization and internationalization of traditional Chinese medicine through innovative research methodologies and technology systems [15][16].